Press Releases

Press Releases

Date Title
March 27, 2018
UNITY Biotechnology, Inc. Appoints Pharmaceutical Industry Executive Paul L. Berns to Board of Directors
SAN FRANCISCO, March 27, 2018 /PRNewswire/ -- UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Paul L. Berns to its board of directors. Mr.
March 19, 2018
UNITY Biotechnology, Inc. Completes $55 Million Series C Financing Proceeds to Support Advancement of Pipeline into Clinical Studies
SAN FRANCISCO, March 19, 2018 /PRNewswire/ -- UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the closing of a $55 million Series C financing.
February 7, 2018
UNITY Biotechnology Adds Accomplished R&D Leader David L. Lacey, M.D., to Board of Directors
SAN FRANCISCO, Feb. 7, 2018 /PRNewswire/ -- UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the appointment of David L. Lacey, M.D., to its board of directors. Dr.
Displaying 11 - 13 of 13